- Home
- SNGX vs NUWE Comparison
SNGX vs NUWE Comparison
Compare SNGX & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- NUWE
- Stock Information
- Founded
- SNGX 1987
- NUWE 1999
- Country
- SNGX United States
- NUWE United States
- Employees
- SNGX N/A
- NUWE N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SNGX Health Care
- NUWE Health Care
- Exchange
- SNGX Nasdaq
- NUWE Nasdaq
- Market Cap
- SNGX 4.3M
- NUWE 3.9M
- IPO Year
- SNGX 1987
- NUWE N/A
- Fundamental
- Price
- SNGX $2.78
- NUWE $5.54
- Analyst Decision
- SNGX Strong Buy
- NUWE
- Analyst Count
- SNGX 1
- NUWE 0
- Target Price
- SNGX $6.00
- NUWE N/A
- AVG Volume (30 Days)
- SNGX 22.2M
- NUWE 190.0K
- Earning Date
- SNGX 08-14-2025
- NUWE 08-14-2025
- Dividend Yield
- SNGX N/A
- NUWE N/A
- EPS Growth
- SNGX N/A
- NUWE N/A
- EPS
- SNGX N/A
- NUWE N/A
- Revenue
- SNGX N/A
- NUWE $8,318,000.00
- Revenue This Year
- SNGX N/A
- NUWE $6.53
- Revenue Next Year
- SNGX N/A
- NUWE $51.63
- P/E Ratio
- SNGX N/A
- NUWE N/A
- Revenue Growth
- SNGX N/A
- NUWE N/A
- 52 Week Low
- SNGX $1.09
- NUWE $4.82
- 52 Week High
- SNGX $5.40
- NUWE $175.98
- Technical
- Relative Strength Index (RSI)
- SNGX 59.82
- NUWE 32.42
- Support Level
- SNGX $2.32
- NUWE $4.82
- Resistance Level
- SNGX $2.99
- NUWE $5.56
- Average True Range (ATR)
- SNGX 0.69
- NUWE 0.71
- MACD
- SNGX 0.02
- NUWE -0.02
- Stochastic Oscillator
- SNGX 38.10
- NUWE 11.25
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.